Is Apelvis a targeted drug?

Alpelisib is a targeted drug. Alpelisib is a phosphatidylinositol3-kinase (PI3K) inhibitor with potent anti-tumor activity. Apelvis was approved by the U.S. Food and Drug Administration in May 2019. It is the first approved treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor2 (her The PI3K inhibitor fulvestrant is suitable for postmenopausal women and male patients with 2)-negative, PIK3CAmutated, advanced or metastatic breast cancer.

Apelixacts by selectively inhibiting the IlikePI3K p110α is the catalytic subunit of PI3K, a lipid kinase that plays a role in a variety of biological processes including proliferation, survival, differentiation, and metabolism. Apelixis designed to target this enzyme, which is mutated in human cancers at a rate approaching 30% leading to overactivation. Apelixdoes not prolong the QTcF interval. Patients taking apelixobtained dose-dependent benefits from the treatment, with a daily 200mg dose advantage over 100mgdose advantage51%, the once-daily 300mg dose has a 22% dosage advantage over the twice-daily 150mg dosage. This suggests that patients requiring lower doses may benefit from twice-daily dosing. Phosphatidylinositol-3-kinase-α (PI3Kα) is responsible for cell proliferation in response to activation of the growth factor-tyrosine kinase pathway. In some cancers, the p110α catalytic subunit of PI3Kα is mutated, making it abnormally active. Apelixinhibits (PI3K), onPI3Kα has the highest specificity. The retail price of the Indian version of the original medicine in pharmacies150mg28 is around three to four thousand per pill. The retail price of the European version in pharmacies is about 150mg56 tablets4 about 10,000 yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.